Gentle second chance: new Valve-in-Valve study for failing heart valves

NCT ID NCT07215143

Not yet recruiting Disease control Sponsor: IHF GmbH - Institut für Herzinfarktforschung Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows about 300 patients across Europe who need a second minimally invasive heart valve replacement (TAVI-in-TAVI) because their first valve has worn out or is leaking. Doctors will use the Myval valve for the replacement. The study will track how well the procedure works and any complications over up to five years, using information from routine medical care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Myval transcatheter heart valve (OctaCor/OctaPRO)
What this could lead to: If successful, this could show that a second TAVI procedure with the Myval valve is a safe and effective alternative to repeat open-heart surgery for patients whose first valve has worn out.
What could go wrong: This is an observational study, not a randomized trial, so it cannot prove the Myval valve is better than other options. Results depend on routine care data, which may be incomplete. The procedure itself carries risks like any heart valve replacement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC VALVE STENOSIS

More trials for these conditions

Other studies related to the condition(s) this trial covers.